Patents by Inventor Birgit Schoeberl
Birgit Schoeberl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150231238Abstract: Provided are methods for overcoming resistance to an ErbB pathway inhibitor, such as an EGFR inhibitor or a HER2 inhibitor. The resistance may be acquired resistance to an EGFR inhibitor, such as acquired resistance to gefitinib. In the methods provided, a subject exhibiting resistance to an ErbB pathway inhibitor is selected and both an ErbB 3 inhibitor and a second ErbB pathway inhibitor are administered to the subject, such as an EGFR inhibitor or a HER2 inhibitor. Also provided are methods for inhibiting the growth of a tumor comprising a T790M EGFR mutation by contacting the tumor with an ErbB3 inhibitor and an EGFR inhibitor. Compositions for overcoming resistance to an ErbB pathway inhibitor, comprising both an ErbB 3 inhibitor and a second ErbB pathway inhibitor, such as an EGFR inhibitor or a HER2 inhibitor, are also provided.Type: ApplicationFiled: March 15, 2012Publication date: August 20, 2015Applicant: MERRIMACK PHARMACEUTICALS, INC.Inventors: Gabriela Garcia, William Kubasek, Maria Johanna Lahdenranta, Gavin MacBeath, Charlotte McDonagh, Victor Moyo, Matthew David Onsum, Birgit Schoeberl, Mark Sevecka, Marisa Wainszelbaum, Bo Zhang
-
Patent number: 8961966Abstract: The present invention provides a novel class of monoclonal antibodies which bind ErbB3 receptor and inhibits various ErbB3 functions. For example, the antibodies described herein are capable of binding to ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor.Type: GrantFiled: October 14, 2010Date of Patent: February 24, 2015Assignee: Merrimack Pharmaceuticals, Inc.Inventors: Birgit Schoeberl, Ulrik Nielsen, Michael Feldhaus, Arumugam Muruganandam, David Buckler
-
Publication number: 20140234329Abstract: The present invention provides a novel class of antibodies and antigen binding fragments thereof that bind the extracellular domain of ErbB3 receptor and inhibit various ErbB3 functions. For example, the antibodies and antigen binding fragments described herein are capable of binding to the receptor designated ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor. Such antibodies and antigen binding fragments thereof have the useful characteristic of inhibiting the proliferation of cancer cells expressing ErbB3.Type: ApplicationFiled: February 14, 2014Publication date: August 21, 2014Applicant: MERRIMACK PHARMACEUTICALS, INC.Inventors: Birgit SCHOEBERL, Ulrik NIELSEN, Michael FELDHAUS, Arumugam MURUGANANDAM, David BUCKLER
-
Publication number: 20140178380Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.Type: ApplicationFiled: February 24, 2014Publication date: June 26, 2014Applicant: Merrimack Pharmaceuticals, Inc.Inventors: Ulrik Nielsen, Thomas Wickham Groton, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
-
Publication number: 20140127238Abstract: The invention provides methods for treating patients which methods comprise methods for predicting responses of cells, such as tumor cells, to treatment with therapeutic agents. These methods involve measuring, in a sample of the cells, levels of one or more components of a cellular network and then computing a Network Activation State (NAS) or a Network Inhibition State (NIS) for the cells using a computational model of the cellular network. The response of the cells to treatment is then predicted based on the NAS or NIS value that has been computed. The invention also comprises predictive methods for cellular responsiveness in which computation of a NAS or NIS value for the cells (e.g., tumor cells) is combined with use of a statistical classification algorithm. Biomarkers for predicting responsiveness to treatment with a therapeutic agent that targets a component within the ErbB signaling pathway are also provided.Type: ApplicationFiled: January 6, 2014Publication date: May 8, 2014Applicant: MERRIMACK PHARMACEUTICALS, INC.Inventors: Birgit SCHOEBERL, Brian HARMS, Francis David GIBBONS, Jonathan Basil FITZGERALD, Matthew David ONSUM, Ulrik NIELSEN, William KUBASEK
-
Patent number: 8691771Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.Type: GrantFiled: May 20, 2011Date of Patent: April 8, 2014Assignee: Merrimack Pharmaceuticals, Inc.Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
-
Patent number: 8691225Abstract: The present invention provides a novel class of antibodies and antigen binding fragments thereof that bind the extracellular domain of ErbB3 receptor and inhibit various ErbB3 functions. For example, the antibodies and antigen binding fragments described herein are capable of binding to the receptor designated ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor. Such antibodies and antigen binding fragments thereof have the useful characteristic of inhibiting the proliferation of cancer cells expressing ErbB3.Type: GrantFiled: August 21, 2009Date of Patent: April 8, 2014Assignee: Merrimack Pharmaceuticals, Inc.Inventors: Birgit Schoeberl, Ulrik Nielsen, Michael Feldhaus, Arumugam Muruganandam, David Buckler
-
Patent number: 8623592Abstract: The invention provides methods for treating patients which methods comprise methods for predicting responses of cells, such as tumor cells, to treatment with therapeutic agents. These methods involve measuring, in a sample of the cells, levels of one or more components of a cellular network and then computing a Network Activation State (NAS) or a Network Inhibition State (NIS) for the cells using a computational model of the cellular network. The response of the cells to treatment is then predicted124 based on the NAS or NIS value that has been computed. The invention also comprises predictive methods for cellular responsiveness in which computation of a NAS or NIS value for the cells (e.g., tumor cells) is combined with use of a statistical classification algorithm. Biomarkers for predicting responsiveness to treatment with a therapeutic agent that targets a component within the ErbB signaling pathway are also provided.Type: GrantFiled: August 17, 2009Date of Patent: January 7, 2014Assignee: Merrimack Pharmaceuticals, Inc.Inventors: Birgit Schoeberl, Brian Harms, Francis David Gibbons, Jonathan Basil Fitzgerald, Matthew David Onsum, Ulrik Nielsen, William Kubasek
-
Publication number: 20120244163Abstract: Disclosed are bispecific binding agents that specifically target both of the IGF-1 and the ErbB intracellular signaling pathways. For example, bispecific binding agents that comprise an anti-IGF-1R antibody and an anti-ErbB3 antibody connected by a linker are described herein. These bispecific agents are capable of antagonizing signal transduction by both of the IGF-1 and the ErbB signaling pathways and are useful in inhibiting the proliferation of tumor cells whose growth involves the signaling activity of both pathways.Type: ApplicationFiled: April 10, 2012Publication date: September 27, 2012Applicants: DYAX CORP., MERRIMACK PHARMACEUTICALS, INC.Inventors: Birgit SCHOEBERL, Ulrik NIELSEN, Arthur J. KUDLA, Arumugam MURUGANANDAM, David BUCKLER, Alexey Alexandrovich LUGOVSKOY, Jonathan Basil FITZGERALD, Lihui XU, Neeraj KOHLI
-
Publication number: 20110293579Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.Type: ApplicationFiled: May 20, 2011Publication date: December 1, 2011Applicant: Merrimack Pharmaceuticals, Inc.Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun Lippow
-
Publication number: 20110286976Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.Type: ApplicationFiled: May 20, 2011Publication date: November 24, 2011Applicant: MERRIMACK PHARMACEUTICALSInventors: ULRIK NIELSEN, THOMAS WICKHAM, BIRGIT SCHOEBERL, BRIAN HARMS, BRYAN LINGGI, MATTHEW ONSUM, BYRON DELABARRE
-
Publication number: 20110159513Abstract: The invention provides methods for treating patients which methods comprise methods for predicting responses of cells, such as tumor cells, to treatment with therapeutic agents. These methods involve measuring, in a sample of the cells, levels of one or more components of a cellular network and then computing a Network Activation State (NAS) or a Network Inhibition State (NIS) for the cells using a computational model of the cellular network. The response of the cells to treatment is then predicted based on the NAS or NIS value that has been computed. The invention also comprises predictive methods for cellular responsiveness in which computation of a NAS or NIS value for the cells (e.g., tumor cells) is combined with use of a statistical classification algorithm. Biomarkers for predicting responsiveness to treatment with a therapeutic agent that targets a component within the ErbB signaling pathway are also provided.Type: ApplicationFiled: August 17, 2009Publication date: June 30, 2011Applicant: MERRIMACK PHARMACEUTICALS, INC.Inventors: Birgit Schoeberl, Brian Harms, Francis David Gibbons, Jonathan Basil Fitzgerald, Matthew David Onsum, Ulrik Nielsen, William Kubasek
-
Publication number: 20110123523Abstract: The present invention provides a novel class of monoclonal antibodies which bind ErbB3 receptor and inhibits various ErbB3 functions. For example, the antibodies described herein are capable of binding to ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor.Type: ApplicationFiled: October 14, 2010Publication date: May 26, 2011Applicant: MERRIMACK PHARMACEUTICALS, INC.Inventors: Birgit SCHOEBERL, Ulrik NIELSEN, Michael FELDHAUS, Arumugam MURUGANANDAM, David BUCKLER
-
Publication number: 20110027291Abstract: The invention provides methods for treating patients which methods comprise methods for predicting responses of cells, such as tumor cells, to treatment with therapeutic agents. These methods involve measuring, in a sample of the cells, levels of one or more components of a cellular network and then computing a Network Activation State (NAS) or a Network Inhibition State (NIS) for the cells using a computational model of the cellular network. The response of the cells to treatment is then predicted based on the NAS or NIS value that has been computed. The invention also comprises predictive methods for cellular responsiveness in which computation of a NAS or NIS value for the cells (e.g., tumor cells) is combined with use of a statistical classification algorithm. Biomarkers for predicting responsiveness to treatment with a therapeutic agent that targets a component within the ErbB signaling pathway are also provided.Type: ApplicationFiled: February 17, 2010Publication date: February 3, 2011Applicant: MERRIMACK PHARMACEUTICALS, INC.Inventors: Birgit SCHOEBERL, Brian HARMS, Francis David GIBBONS, Jonathan Basil FITZGERALD, Matthew David ONSUM, Ulrik NIELSEN, William KUBASEK
-
Patent number: 7846440Abstract: The present invention provides a novel class of monoclonal antibodies which bind ErbB3 receptor and inhibits various ErbB3 functions. In a particular embodiment, the antibodies are capable of binding to ErbB3 and inhibiting ligand mediated phosphorylation of the receptor.Type: GrantFiled: February 15, 2008Date of Patent: December 7, 2010Assignee: Merrimack Pharmaceuticals, Inc.Inventors: Birgit Schoeberl, Ulrik Nielsen, Michael Feldhaus, Arumugam Muruganandam, David Buckler
-
Publication number: 20100266584Abstract: The present invention provides a novel class of antibodies and antigen binding fragments thereof that bind the extracellular domain of ErbB3 receptor and inhibit various ErbB3 functions. For example, the antibodies and antigen binding fragments described herein are capable of binding to the receptor designated ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor. Such antibodies and antigen binding fragments thereof have the useful characteristic of inhibiting the proliferation of cancer cells expressing ErbB3.Type: ApplicationFiled: August 21, 2009Publication date: October 21, 2010Applicants: MERRIMACK PHARMACEUTICALS, INC., DYAX CORP.Inventors: Birgit SCHOEBERL, Ulrik NIELSEN, Michael FELDHAUS, Arumugam Muruganandam, David Buckler
-
Publication number: 20100056761Abstract: The present invention provides a novel class of monoclonal antibodies which bind ErbB3 receptor and inhibits various ErbB3 functions. For example, the antibodies described herein are capable of binding to ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor.Type: ApplicationFiled: April 17, 2009Publication date: March 4, 2010Applicants: MERRIMACK PHARMACEUTICALS, INC., DYAX CORPInventors: Birgit SCHOEBERL, Ulrik NIELSEN, Michael FELDHAUS, Arumugam Muruganandam, David Buckler
-
Publication number: 20090291085Abstract: The present invention provides a novel class of monoclonal antibodies which bind ErbB3 receptor and inhibits various ErbB3 functions. For example, the antibodies described herein are capable of binding to ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor.Type: ApplicationFiled: February 15, 2008Publication date: November 26, 2009Applicant: MERRIMACK PHARMACEUTICALS, INC.Inventors: Birgit Schoeberl, Ulrik Nielsen, Michael Feldhaus